Should You Buy Boston Scientific Corporation Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Boston Scientific Corporation (BSX) is rated as a strong fundamental performer with a QOC score of 8.9/10. Trading at $43.87, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 5 of 11 CirclFi valuation models project upside for Boston Scientific Corporation (BSX) at $43.87 — the model consensus leans bearish, with a Quality Score of 8.9/10 and Value-Trap risk of 17/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Boston Scientific Corporation (BSX) in 2026?
What Is the Bull Case vs the Bear Case for Boston Scientific Corporation (BSX)?
| Bull case — $79.32 target (+80.8%) | Bear case — $9.78 target (-77.7%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Boston Scientific Corporation's rating of 8.9/10 signals strong fundamentals — high-quality businesses tend to compound value more reliably. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $9.78 (-77.7%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model targets a fair value of $79.32 (+80.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +158.5% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| Industry tailwind: late-stage pipeline catalysts could provide meaningful support for Boston Scientific Corporation's revenue and margin trajectory in the Medical Devices space. | Industry headwind: regulatory rejection risk represents a meaningful risk for Boston Scientific Corporation and its Medical Devices peers. |
| The company's $63.6B market capitalization provides liquidity, stability, and the resource base to invest through downturns — structural advantages over smaller peers. |
How Does BSX Compare to Its Medical Devices Peers?
Valuation data pages: INSP · PEN · SYK · ABT · ELMD · STE · IRTC · RPID · FEED · IRMD · PODD
Which Other Stocks Score Like BSX on Quality?
Closest companies to BSX’s Quality of Company score of 8.9/10, across all industries.
- CPAC — Cementos Pacasmayo S.A.A. (QOC 8.9) · analysis
- ACLS — Axcelis Technologies, Inc. (QOC 8.9) · analysis
- PAYX — Paychex, Inc. (QOC 8.9) · analysis
- KEYS — Keysight Technologies, Inc. (QOC 8.9) · analysis
- MGY — Magnolia Oil & Gas Corporation (QOC 8.9) · analysis
- KO — The Coca-Cola Company (QOC 8.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Devices Screens Does BSX Appear In?
So Is Boston Scientific Corporation (BSX) Worth Buying in 2026?
Our models don't have a clear verdict on Boston Scientific Corporation. At $43.87 vs. $40.71 median fair value, the median upside of -7.2% masks significant model disagreement (+158.5% spread). With quality at 8.9/10, this is a stock where the margin of error is wide and additional fundamental research is strongly recommended.
These are quantitative model outputs, not investment recommendations. Boston Scientific Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About BSX Stock?
Should I buy BSX stock right now?
Based on CirclFi's multi-model analysis, 5 of 11 models see upside for BSX at $43.87. The models are divided, which means the investment case depends heavily on your assumptions about Boston Scientific Corporation's future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Boston Scientific Corporation?
Key risks include: wide model disagreement (711% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Devices companies. Always diversify and consult a financial advisor.
How does BSX compare to its competitors?
Among Medical Devices peers, BSX holds a Quality Score of 8.9/10. Comparable companies include INSP (QOC 9.0), PEN (QOC 8.9), SYK (QOC 9.0). The relative ranking helps investors identify whether BSX offers better fundamental quality than alternatives in the same sector.
Is BSX a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. BSX's Quality Score of 8.9/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy BSX at?
CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $9.78 to $79.32. At $43.87, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for BSX.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad